Wellmarker Bio announced its first-in-class colon cancer drug candidate(WM-S1-030)’s abstract was selected at the American Society of Clinical Oncology(ASCO), held on May 29 – 31, 2020 online. ASCO is the world’s largest cancer conference, which 40,000 experts attending annually.
Wellmarker Bio presented the validation data of predictive biomarker and the result of CTC analysis before and after WM-S1-030 administration in animal model. Details of the abstract can be found as follows.
Pipeline: WM-S1(Colon cancer treatment)
Title: Prediction and prognostic validation of colorectal cancer therapeutic effect of WM-S1-030 using pre-clinical CTC animal model.